The findings of a pan-cancer study have indicated that all patients with microsatellite instability-high (MSI-H) tumors should be tested for Lynch syndrome, regardless of cancer type or their personal or family history of cancer.
Analyzing cell-free DNA (cfDNA) circulating in plasma or serum can help oncologists determine the genotype of tumors noninvasively to guide treatment decisions and may eventually allow them to monitor treatment response, predict recurrence, and screen for cancer.
Rearranged during transfection (RET) is an oncogene activated by RET fusions or RET mutations. RET fusions are associated with 2% of non–small cell lung cancers (NSCLCs), 10%-20% of papillary and other thyroid cancers, and smaller proportions of other cancers.
The Clinical Science Symposium, “Precision Medicine: Making Progress for Patient Benefit,” detailed 3 large-scale efforts leveraging innovative trial designs and cutting-edge technology to break critical ground in the ability to pinpoint and use viable targeted therapies for individual patients.
Because immune responses are evolving and dynamic over time, expression of a single biomarker to select patients for treatment will really not be feasible and we should not continue on the single biomarker path.
Several Education Sessions focus on the increasing importance of immunotherapies in oncology practice and on future research directions in the field. From currently approved checkpoint inhibitors to on-the-horizon ideas, these sessions offer glimpses into a promising area of cancer therapy.
The field of immuno-oncology has revolutionized cancer care over the past decade and continues to yield new, exciting results. ASCO, in collaboration with the Society for Immunotherapy of Cancer (SITC), will be holding its first symposium on immuno-oncology next year in Orlando, Florida.
Wendy Kohlmann, Marjan Champine, and Dr. Sarah Colonna present their thoughts on discussing genetic testing with patients and their families, including obtaining informed consent, explanation of mutations, and recommendations for genetic counseling.
Results from the phase III IFCT-GFPC-0701 MAPS trial found that the addition of bevacizumab to standard chemotherapy in patients with malignant pleural mesothelioma prolonged overall survival by 2.75 months.
Advances made in next generation sequencing have allowed germline mutations to be increasingly identified in tumors and normal DNA. The significance of these findings, including whether results arising from germline testing should be returned to patients, was discussed during this session.